Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
Figure 2
SHP1/AMPK pathway was involved in relieving effects of liraglutide on NAFLD in vivo. (a) The changes of levels of SHP1/AMPK pathway in all groups. SHP1, p-AMPK, AMPK, p-ACC, and ACC were detected by western blot and the representative images are shown. (b) The densitometry ratio of SHP1/GAPDH, p-AMPK/AMPK, and p-ACC/ACC are shown as mean ± SD of three independent experiments. (c) The changes of levels of lipid metabolic proteins expression in all groups. CPT-1a, FAS, and SREBP-1c were detected by western blot and the representative images are shown. (d) The densitometry ratio of CPT-1a/GAPDH, FAS/GAPDH, and SREBP-1c/GAPDH are shown as mean ± SD of three independent experiments. (e) The changes of levels of gluconeogenic proteins expression in all groups. G6Pase and PEPCK were detected by western blot and the representative images are shown. (f) The densitometry ratio of G6Pase/GAPDH and PEPCK/GAPDH is shown as mean ± SD of three independent experiments. The western blot results were normalized to the HFD group value. n.s. denotes no significance. denotes P < 0.05 versus the HFD+Veh group. # denotes P < 0.05 versus the HFD+LR+LV-CTL group. & denotes P < 0.05 versus the HFD+LR+LV-SHP1 group.